Introduction {#Sec1}
============

Many papers have described the COVID-19 patient population \[[@CR1], [@CR2]\]. The majority have reported clinical features in hospitalized with or without ICU admission, mostly in China and more recently in Italy \[[@CR3], [@CR4]\]. Yet, most of the patients in these countries were managed in an outpatient setting. This population has been excluded of the studies and its characteristics are poorly documented.

In France, health authorities were quick to recommend outpatient management of patients with suspected or confirmed COVID-19 infection who presented with mild-to-moderate symptoms. Patients were asked to contact the emergency medical system (SAMU) with their questions and in the event of worsening symptoms. SAMU can be reached with a single national toll-free number, nationwide, '15' \[[@CR5]\]. Since the beginning of the epidemic in Europe at the end of February, the number of calls increased dramatically, up to 400% of normal call volume. After an initial assessment by an EMS regulator, patients with less severe symptoms were not immediately connected to the emergency physician dispatcher, but received a follow-up telephone call within the following 12 h. This is the patient cohort studied here. The aim of this study was to describe the clinical characteristics of a large cohort of COVID-confirmed patients managed in outpatient settings, and to compare this clinical feature with previously published features.

Methods {#Sec2}
=======

Site {#Sec3}
----

The study took place in SAMU 93 emergency medical dispatching center located in the Seine-Saint-Denis district of the Greater Paris, north-east of Paris proper. This district encompasses a population of 1.6 million for an area of 236 km^2^, making it one of the most densely populated districts in France; it is also the most socioeconomically disadvantaged district. Our call center received 750,000 calls in 2019, resulting in the management of 250,000 patients.

Procedure {#Sec4}
---------

During the study period, patients were included in our prospective observational survey if they met confirmed COVID-19 infection criteria according to the WHO definition, i.e., positive PCR or fever (during the last 48 h) and dry cough (<https://www.who.int>). We investigated clinical features and classified symptoms as general symptoms (body aches/myalgia, headache, and asthenia), digestive symptoms (anorexia, nausea, vomiting, and diarrhea), ear--nose--throat symptoms (pharyngalgia, rhinopharyngitis, anosmia and ageusia), respiratory and chest symptoms (shortness of breath, chest pain, and hemoptysis), and eye disease. Finally, the decision whether or not to transfer the patient to the hospital was recorded. As patients were asked to call back the SAMU in case of worsening symptoms, only the first call was considered an inclusion criterion. Patients were included between March 24 and April 6.

Analysis and ethics {#Sec5}
-------------------

Our primary aim was to compare clinical features of COVID-19 infection in male and female patients. We also compared clinical features based on the main inclusion criteria, positive PCR vs clinically confirmed COVID-19.

The aim was to include 1500 consecutive patients. The management of the patients was not affected by the study. According to French law, the study was recorded at the Commission Nationale Informatique et Liberté (CNIL 1881609), the French national data protection authority. Qualitative date was compared using a Chi-square test; quantitative date was compared using a Student *T* test. A *p* value \< 0.05 was considered as significant. Results are expressed as *N* (%) or median (IQ). Statistical analysis was performed using R 3.6.3.

Results {#Sec6}
=======

During the study period, 5104 patients were screened as having no signs of severity and 1487 (29%) were included: 700 (47%) patients were male and 752 (51%) were female (missing data: *N* = 35) with a median age of 44 (32--57) years. Among these patients, 28 (2%) were aged under 16 years and 12 (1%) under 10. COVID-19 infection was diagnosed according to clinical symptoms (fever + cough) in 1351 (91%) cases and according to PCR test in 197 (13%) cases.

In addition to dry cough and fever (inclusion criteria) reported in more than 90% of cases, the most common symptoms were general symptoms: body aches/myalgia (*N* = 845; 57%), headache (*N* = 824; 55%), asthenia (*N* = 886; 60%); ear--nose--throat symptoms such as anosmia (*N* = 415; 28%), ageusia (*N* = 422; 28%), ageusia and anosmia (*N* = 335; 23%), and shortness of breath (*N* = 479; 32%). Chest pain was reported in 320 (22%) cases and hemoptysis in 41 (3%) cases. Complete results are reported in Fig. [1](#Fig1){ref-type="fig"}. The main difference between male and female patients was the prevalence of ear--nose--throat symptoms (Table [1](#Tab1){ref-type="table"}). Chest pain and headaches were also more frequent in female patients.

After assessment by phone, 83 (6%) patients were transferred to the hospital, without significant difference in terms of gender.Fig. 1Symptom prevalence in a cohort of COVID-19 patients managed in outpatient settings (*N* = 1487). Results are presented by rate with a 95% confidence intervalTable 1Comparison of symptom prevalence between male and female patients in a cohort of COVID-19 patients managed in outpatient settings (*N *= 1487)MaleFemale*pN*700 (48%)752 (52%)Age (years)44 \[32--57\]41 \[30--54\]0.3Inclusion criteria COVID-confirmed81 (11%)109 (14%)0.1 Dry cough661 (94%)707 (94%)0.8 Fever658 (94%)686 (91%)0.06General symptoms Ache/myalgia379 (54%)444 (59%)0.07 Headache341 (49%)462 (61%) \< 0.0001 Asthenia430 (61%)434 (58%)0.2Digestive symptoms Anorexia156 (22%)149 (20%)0.3 Nausea122 (17%)166 (22%)0.03 Vomiting75 (11%)93 (12%)0.4 Diarrhea153 (22%)199 (26%)0.047Ear--nose--throat symptoms Pharyngalgia159 (23%)218 (29%)0.008 Rhinopharyngitis85 (12%)122 (16%)0.03 Anosmia169 (24%)237 (32%)0.002 Ageusia176 (25%)238 (32%)0.007Respiratory and chest symptoms Shortness of breath213 (30%)250 (33%)0.3 Chest pain127 (18%)181 (24%)0.007 Hemoptysis22 (3%)17 (3%)0.4 Eye disease24 (3%)38 (5%)0.2 Transfer hospital35 (5%)44 (6%)0.6Results are presented as *N* (%) or \[IQ\]

Results of the comparison between clinical features in patients with positive PCR and those with clinically confirmed COVID-19 are reported in the Supplementary Annexes. Patients with positive PCR were younger and complained less frequently of body aches and asthenia and more frequently of vomiting and shortness of breath.

Discussion {#Sec7}
==========

The clinical features of COVID-19 infection in this large cohort of patients managed in outpatient settings were extremely varied. As previously reported, general symptoms, i.e., flu-like symptoms such as fever, cough, and asthenia, and body aches and headaches were the most frequent symptoms. Female patients were more likely to present ear--nose--throat symptoms, chest pain, and headaches than male patients.

Our first aim was to describe the symptoms observed in patients who received outpatient care. We were able to complete this goal, as only 5% of patients were transferred to the hospital after medical evaluation by the emergency physician dispatcher. As 80% of COVID-19 patients worldwide are managed in outpatient settings, we postulate that the clinical features described here apply to most COVID-19 patients. Consequently, in our study, sex ratio is close to the global population. It contrasts with the in-hospital patient population which is predominantly male in ICU and other hospital departments \[[@CR4], [@CR6]--[@CR8]\].

Anosmia and ageusia have become cardinal signs of COVID-19, but these symptoms were under-reported in the first papers from China. Its prevalence was higher in our findings than previously reported in Chinese and Italian papers, which report these symptoms in 5--6% and 19% of cases, respectively \[[@CR9], [@CR10]\]. These symptoms appear to be more prevalent in patients presenting mild-to-moderate symptoms \[[@CR11]\]. The physiopathology of anosmia and ageusia is still unclear. As this symptom is infrequent in clinical practice, it should be considered a sensitive diagnostic criterion \[[@CR10]\].

A few recent papers have described the clinical features of mild-to-moderate COVID-19 in hospitalized patients \[[@CR12]--[@CR14]\]. General symptoms such as anosmia, asthenia, headaches, and myalgia were the most frequently reported symptoms. A score based on these symptoms has been proposed \[[@CR13]\].

Chest pain was frequent, occurring in 20% of cases, and can be explained by pulmonary disease and severe coughing. However, specific injuries such as pericarditis and myocarditis as well as pulmonary embolism have been found \[[@CR15]--[@CR17]\]. Cardiovascular complications seem to be largely involved in critical outcome \[[@CR18]\]. Nevertheless, we currently are unsure of the relevance of investigating chest pain with electrocardiogram and echocardiography in paucisymptomatic patients. Moreover, due to the high prevalence of chest pain, it was unrealistic to propose systematic investigations.

Hemoptysis was not uncommon. Recent emergency medicine papers on pulmonary embolisms, which is the most frequent cause of hemoptysis in emergency medicine, reveal that hemoptysis occurred in 2--8% of pulmonary embolisms \[[@CR19], [@CR20]\].

Limitations {#Sec8}
===========

The main limit of this study is the lack of definitive COVID infection confirmation by RT-PCR. However, we based ourselves on the WHO's inclusion criteria. The second limit is the lack of clinical assessment. Symptoms were reported by patients and not directly recorded by a physician. Due to the overload of the emergency medical system, we opted to employ this more realistic strategy. For this reason, we decided to manage these patients at home, in an outpatient setting. The third limit is the lack of follow-up. For similar reasons, this was not feasible.

Conclusion {#Sec9}
==========

In this original and large cohort of confirmed COVID-19 patient population managed in outpatient settings in the greater Paris area, symptoms were different from those previously reported. Digestive and ear--nose--throat symptoms were frequent.
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